Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Lewy body dementia (LBD) is misdiagnosed as Alzheimer’s disease in roughly 50% of cases because both conditions cause progressive cognitive decline and share many overlapping symptoms—memory loss, confusion, and difficulty thinking clearly. The critical difference lies in where abnormal protein deposits accumulate in the brain: Alzheimer’s involves amyloid and tau plaques, while LBD is characterized by Lewy bodies, spherical protein clusters made of alpha-synuclein. A 73-year-old man diagnosed with Alzheimer’s after two years of memory problems and confusion was eventually found to have LBD only when he developed hallucinations and rigid movements—symptoms his doctors initially overlooked.
The early misdiagnosis mattered because LBD and Alzheimer’s respond differently to medications, and some Alzheimer’s treatments can actually worsen LBD symptoms. Because autopsy remains the gold standard for confirming Lewy body dementia, many patients live their entire illness being treated for the wrong disease. Brain imaging, cognitive testing, and clinical evaluation can suggest LBD, but they cannot definitively rule out Alzheimer’s or other dementias without tissue confirmation. This diagnostic uncertainty is more than academic—it affects treatment decisions, medication choices, and families’ understanding of what to expect as the disease progresses.
Table of Contents
- What Do Lewy Bodies and Alzheimer’s Pathology Have in Common?
- The Core Symptoms That Drive Misdiagnosis
- How Hallucinations and Movement Problems Create Diagnostic Confusion
- How Doctors Currently Try to Distinguish Lewy Body Dementia from Alzheimer’s
- Why Some Alzheimer’s Medications Worsen Lewy Body Dementia
- Sleep Disturbances and Fluctuating Alertness as Diagnostic Clues
- Autopsy Findings and What They Reveal About Misdiagnosis Rates
What Do Lewy Bodies and Alzheimer’s Pathology Have in Common?
Both Alzheimer’s disease and Lewy body dementia damage the same brain regions responsible for memory, thinking, and movement control. Both involve the gradual death of nerve cells, loss of cognitive function, and progressive decline over years. A patient with either condition might struggle to remember recent conversations, get lost in familiar places, or have difficulty managing finances—behaviors that look identical to family members and often lead to similar initial diagnoses. The overlap becomes apparent in clinical practice: doctors see a patient with progressive memory loss and cognitive decline, and without specialized testing or clear hallmark symptoms, they often assume Alzheimer’s because it is more common, accounting for 60–80% of dementia cases, while LBD accounts for only 5–10%.
Both conditions also develop insidiously, with symptoms that worsen gradually over months and years rather than appearing suddenly. A person might be functioning normally one month and noticeably forgetful the next, without any obvious trigger. What complicates diagnosis further is that Lewy bodies and Alzheimer’s pathology can coexist in the same brain—a condition called mixed pathology. Autopsy studies show that roughly 20% of dementia cases involve Lewy bodies alongside Alzheimer’s plaques and tangles, making it impossible to know which pathology is driving the person’s symptoms without microscopic examination of brain tissue after death.
The Core Symptoms That Drive Misdiagnosis
The cognitive symptoms of Lewy body dementia and Alzheimer’s overlap so significantly that doctors struggle to distinguish them at the bedside. Both involve memory loss, difficulty concentrating, disorientation to time and place, and problems with language and decision-making. A doctor performing a standard cognitive screening test—asking about the current date, repeating words, copying drawings—often gets similar results from LBD and Alzheimer’s patients. However, certain symptoms should raise suspicion for Lewy body dementia but are often missed. Visual hallucinations, particularly detailed and recurring ones, occur in up to 80% of LBD cases but are rare in early Alzheimer’s—yet families sometimes don’t mention hallucinations at appointments, or doctors don’t ask directly.
Movement problems, including slowness, stiffness, tremor, and balance difficulties, appear in LBD but not in typical Alzheimer’s. One 68-year-old woman with LBD was told her Parkinson’s-like symptoms were “just part of aging” by her primary care doctor, while her memory problems were attributed to Alzheimer’s; only later did a neurologist recognize the movement disorder as parkinsonism, a key LBD feature. The critical limitation is that doctors must ask detailed questions about symptoms beyond memory loss. Many primary care physicians spend 15 minutes with a patient and rely on brief cognitive screening tools that miss hallucinations, movement problems, and sleep disturbances characteristic of LBD. Without actively screening for these features, the diagnosis defaults to Alzheimer’s—the most common dementia—even when a different disease is responsible.
How Hallucinations and Movement Problems Create Diagnostic Confusion
Lewy body dementia often produces hallucinations early in the illness, sometimes before significant memory loss. These are typically visual—seeing people, animals, or objects that aren’t there—and they feel very real to the person experiencing them. A patient might see a child sitting in an empty chair or animals walking through the living room, describing them in specific detail. These hallucinations persist over weeks or months and remain consistent; the patient isn’t confused about what they’re seeing—they genuinely perceive it as happening. Doctors sometimes misinterpret LBD hallucinations as psychiatric symptoms, attributing them to depression, anxiety, or early psychosis, especially in younger patients.
One 62-year-old man with LBD who reported seeing people in his home was prescribed an antipsychotic medication that actually worsened his condition—a known risk with certain antipsychotics in LBD, which can cause severe medication sensitivity and neuroleptic malignant syndrome. His hallucinations might have been managed differently if recognized as a neurological symptom of LBD rather than a psychiatric problem. Movement disturbances in LBD include rigidity (stiffness in limbs), slowness of movement, tremor, and postural instability, resembling Parkinson’s disease. Some LBD patients develop these movement features before cognitive decline becomes obvious, leading to initial diagnosis of Parkinson’s disease rather than a dementia. The diagnostic confusion is compounded because a condition called Parkinson’s disease dementia (where Parkinson’s precedes cognitive decline by years) is distinct from Lewy body dementia with parkinsonism (where cognitive and motor symptoms emerge together or with cognitive symptoms first). The presence of parkinsonism without a clear Parkinson’s history should prompt consideration of LBD, but this distinction is often missed.
How Doctors Currently Try to Distinguish Lewy Body Dementia from Alzheimer’s
Clinical diagnosis of Lewy body dementia relies on identifying a cluster of features: cognitive decline, movement problems, hallucinations, and sleep disturbances occurring together. A neurologist will take a detailed history, asking specifically about hallucinations, movement symptoms, dreams, and falls—details that help separate LBD from Alzheimer’s. However, this type of detailed assessment takes time and expertise, and many patients are evaluated only by primary care physicians or geriatricians without neurology training. Brain imaging, including MRI and PET scans, can show patterns suggestive of LBD versus Alzheimer’s. In Alzheimer’s, atrophy tends to involve the medial temporal lobe; in LBD, the occipital lobe is often relatively preserved.
PET imaging can reveal amyloid and tau deposition in Alzheimer’s or dopamine depletion in LBD, but these tests are expensive, not universally available, and must be interpreted alongside clinical features. A 79-year-old woman with LBD had a normal amyloid PET scan, which her neurologist correctly recognized as supporting LBD diagnosis rather than Alzheimer’s—yet general practitioners might have assumed a normal amyloid scan meant “no dementia,” missing the diagnosis entirely. The tradeoff is that these specialized tests improve diagnostic accuracy but require referral to specialists, increasing cost and delay. A patient might see their primary care doctor with memory problems, get diagnosed with Alzheimer’s, and start medications, only to have the diagnosis revised months or years later when symptoms progress in unexpected ways or when a specialist becomes involved. Early neurologist evaluation can prevent this error but is not routine practice in many settings.
Why Some Alzheimer’s Medications Worsen Lewy Body Dementia
Cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, are standard treatments for Alzheimer’s disease and are often prescribed empirically for dementia before a specific diagnosis is confirmed. These medications work by increasing acetylcholine levels in the brain, improving memory and thinking in Alzheimer’s patients. However, they can have different effects in LBD. In Lewy body dementia, cholinesterase inhibitors sometimes improve hallucinations and cognitive function, making them cautiously useful in LBD. The danger emerges with neuroleptic medications—antipsychotics used to manage hallucinations and agitation.
These drugs carry a specific warning in LBD: they can trigger severe, sometimes fatal neuroleptic malignant syndrome, characterized by high fever, muscle rigidity, altered consciousness, and kidney failure. A patient with LBD misdiagnosed as having Alzheimer’s plus behavioral problems might be prescribed haloperidol or risperidone for agitation, medications that pose serious risk in LBD. One family reported that their relative with LBD became critically ill and nearly died within days of starting an antipsychotic; the diagnosis of LBD only emerged after emergency hospitalization. This medication sensitivity is not merely theoretical—it reflects fundamental differences in how dopamine and acetylcholine systems function in LBD versus Alzheimer’s. The warning against antipsychotics in LBD is explicit in clinical guidelines, yet misdiagnosed LBD patients may receive these drugs if their LBD diagnosis is never recognized, exposing them to preventable harm.
Sleep Disturbances and Fluctuating Alertness as Diagnostic Clues
Lewy body dementia characteristically involves abnormal sleep, including REM sleep behavior disorder, where people physically act out vivid dreams—kicking, punching, or jumping out of bed during sleep. This symptom is highly specific to LBD among dementias and appears in up to 80% of cases. Families often describe the person “fighting” or “being chased” during sleep, sometimes for months before any cognitive symptoms emerge.
Daytime fluctuations in alertness and attention, where the person is sharp one hour and confused the next, also characterize LBD more than Alzheimer’s. In Alzheimer’s, cognitive decline is relatively steady; in LBD, these dramatic hour-to-hour fluctuations can mimic delirium or be mistaken for depression. A 70-year-old man with LBD who was alert and conversant during morning doctor’s visits but confused and drowsy by afternoon was told “you’re fine” based on the morning evaluation, his actual illness obscured by the timing of the assessment. When LBD is suspected, doctors should specifically ask about nighttime behaviors and daytime fluctuations, clues that point away from Alzheimer’s.
Autopsy Findings and What They Reveal About Misdiagnosis Rates
Autopsy studies examining brain tissue after death provide the gold standard for determining what dementia a person actually had during life. These studies consistently show that 25–50% of patients clinically diagnosed with Alzheimer’s during life actually had Lewy body dementia or a mixture of pathologies. Conversely, some patients diagnosed clinically with Parkinson’s disease or other conditions had predominantly Lewy body dementia as the cause of their cognitive decline.
One research study following 100 dementia patients found that 26% had a different pathological diagnosis at autopsy than their clinical diagnosis during life, with many of these misdiagnoses involving unrecognized Lewy body pathology. These autopsy findings underscore that clinical diagnosis, while improved with specialist evaluation, remains imperfect. Brain biopsy or other definitive tests during life could improve diagnostic certainty, but they carry risks and are rarely performed except in research settings. The gap between clinical diagnosis and actual pathology remains one of the most sobering realities in dementia care.
- —
